3300-67-2

Usage

Uses

Used in Polymer and Adhesive Production:
o-CHLOROSTYRYL PHENYL KETONE is used as a photoinitiator for the production of polymers and adhesives. Its ability to initiate polymerization upon exposure to light makes it a valuable component in the manufacturing process.
Used in UV-Curable Inks and Coatings:
o-CHLOROSTYRYL PHENYL KETONE is used as a photoinitiator in UV-curable inks and coatings. Its photoreactivity allows for rapid curing of these materials under ultraviolet light, improving production efficiency and reducing energy consumption.
Used in Dental Materials:
o-CHLOROSTYRYL PHENYL KETONE is used as a photoinitiator in dental materials, such as dental resins and composites. Its ability to generate free radicals upon light exposure facilitates the curing process, providing a fast and efficient method for dental restorations.
Used in Photodynamic Therapy:
o-CHLOROSTYRYL PHENYL KETONE has been studied for its potential as a photoinitiator in photodynamic therapy, a treatment for cancer and other diseases that involves the use of light-activated drugs. Its ability to generate singlet oxygen when exposed to light makes it a promising candidate for this application.
Used in Medical and Industrial Processes:
o-CHLOROSTYRYL PHENYL KETONE's ability to generate singlet oxygen upon light exposure has implications for its use in various medical and industrial processes. This property can be harnessed for applications such as sterilization, disinfection, and the development of new materials with unique properties.

Upstream product

• 89-98-5 2-chloro-benzaldehyde 
• 98-86-2 acetophenone 
• 70-11-1 α-bromoacetophenone 
• 79-04-9 chloroacetyl chloride 
• 109-77-3 malononitrile 
• 20913-05-7 (Benzoylmethylene)triphenylphosphorane 
• 536-74-3 phenylacetylene 
• 614-47-1 1,3-diphenyl-propen-3-one 
• 2142-68-9 1-(2-chlorophenyl)ethanone 
• 100-52-7 benzaldehyde 

Downstream Products

• 6631-07-8 [4-(2-Chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-phenyl-methanone 
• 74007-58-2 2-(2-Chloro-phenyl)-3,3-dimethoxy-1-phenyl-propan-1-one 
• 74007-63-9 3-(2-Chloro-phenyl)-3-methoxy-2-phenyl-propionic acid methyl ester 
• 94360-55-1 cis-1-benzoyl-2-(2-chlorophenyl)-3,3-dicyanocyclopropane 
• 96570-10-4 6-Benzoyl-5-(2-chloro-phenyl)-3-methoxy-cyclohex-2-enone 
• 127143-06-0 ethyl 2-oxo-6-(2-chlorophenyl)-4-phenyl-3-cyclohexene-1-carboxylate 
• 133961-77-0 [1-(2-Chloro-phenyl)-3-oxo-3-phenyl-propylsulfanyl]-acetic acid 
• 80824-88-0 2-[1-(2-Chloro-phenyl)-3-oxo-3-phenyl-propylsulfanyl]-benzoic acid 
• 94360-03-9 2-(1-(2-chlorophenyl)-3-oxo-3-phenylpropyl)malononitrile 
• 133961-84-9 3-[1-(2-Chloro-phenyl)-3-oxo-3-phenyl-propylsulfanyl]-propionic acid 
• 24213-14-7 (1RS:2SR)-1.2-dibromo-3-phenyl-1-(2-chloro-phenyl)-propanone-⁽³⁾ 
• 77198-47-1 2-amino-4-(2-chlorophenyl)-6-phenylbenzene-1,3-carbodinitrile 
• 94360-26-6 2-Bromo-4-(2-chloro-phenyl)-6-phenyl-nicotinonitrile 
• 94360-71-1 3-Amino-4-(2-chloro-phenyl)-6-phenyl-thieno[2,3-b]pyridine-2-carbonitrile 

Relevant academic research and scientific papers

Synthesis of 7-oxabicyclo[2.2.1]hept-5-en-2-yl derivatives and their screening for antimicrobial and antioxidant properties

Novel 7-oxabicyclo[2.2.1]hept-5-en-2-yl derivatives have been synthesized using boron trifluoride diethyl etherate catalyzed Diels-Alder reaction. This method presents considerable synthetic advantages in terms of high atom economy, mild reaction conditio

Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy

In search for new and safer anti-cancer agents, a structurally guided pharmacophore hybridization strategy of two privileged scaffolds, namely diaryl pyrazolines and imidazolidine-2,4-dione (hydantoin), was adopted resulting in a newfangled series of compounds (H1-H22). Herein, a bio-isosteric replacement of “pyrrolidine-2,5-dione” moiety of our recently reported antitumor hybrid incorporating diaryl pyrazoline and pyrrolidine-2,5-dione scaffolds with “imidazoline-2,4-dione” moiety has been incorporated. Complete biological studies revealed the most potent analog among all i.e. compound H13, which was at-least 10-fold more potent compared to the corresponding pyrrolidine-2,5-dione, in colon and breast cancer cells. In-vitro studies showed activation of caspases, arrest of G0/G1 phase of cell cycle, decrease in the expression of anti-apoptotic protein (Bcl-2) and increased DNA damage. In-vivo assay on HT-29 (human colorectal adenocarcinoma) animal xenograft model unveiled the significant anti-tumor efficacy along with oral bioavailability with maximum TGI 36% (i.p.) and 44% (per os) at 50 mg/kg dose. These findings confirm the suitability of hybridized pyrazoline and imidazolidine-2,4-dione analog H13 for its anti-cancer potential and starting-point for the development of more efficacious analogs.

Facile microwave-assisted synthesis and antitubercular evaluation of novel aziridine derivatives

Novel 2-(aryloxymethyl)aziridines and 2-((3-aryl-1-phenylallyloxy)methyl)aziridine derivatives were prepared via ring-opening reaction of epoxides. The synthesized derivatives were characterized by using elemental analysis (EA), FT-IR, 13C NMR, and 1H NMR. The in vitro antitubercular activities of the synthesized compounds were evaluated against Mycobacterium tuberculosis H37Rv (MTB H37Rv) strain using MTT-MABA assay. All the aziridine derivatives exhibited improved persuasive antitubercular activity against MTB H37Rv in comparison with standard drugs. Among the tested compounds, 2-(naphthalene-1-yloxy) methyl aziridine (5b), 2-(naphthalene-2-yloxy)methylaziridine (5c), 2-(m-tolyloxymethyl)aziridine (5e), 2-(3-(4-methoxyphenyl)-1-phenylalloxy)methylaziridine (12b) and 2-(3-(2-chlorophenyl)-1-phenylallyloxy)methylaziridine (12c) revealed promising activity against MTB H37Rv. Specifically, compound 5b and 12 b showed three-times more active (MIC = 0.5 μg/mL) than the standard drugs ethambutol (MIC = 1.56 μg/mL) and ciprofloxacin (MIC = 1.56 μg/mL).

Rapid umpolung Michael addition of isatin N, N ′-cyclic azomethine imine 1,3-dipoles with chalcones

The umpolung Michael addition of isatin N,N′-cyclic azomethine imine 1,3-dipoles with chalcones is reported. The reaction could be finished within a very short time (0.3-2 min), with 3,3-disubstituted oxindole derivatives obtained in moderate to excellent yields with promising dr values. Unusual Michael adducts were obtained in moderate to high yields (26-98%) with low to high diastereoselectivities (0.8: 1 to 8.5: 1 dr). All the synthesized compounds (3, 3′, 4, 5, 5′, 7, 7′, 9 and 9′) were well characterized by FTIR, NMR, and mass spectral analyses and further confirmed by the single-crystal X-ray diffraction analysis of compounds 3aa and 4n.

Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks

In anticancer drug discovery, multi-targeting compounds have been beneficial due to their advantages over single-targeting compounds. For instance, VEGFR-2 has a crucial role in angiogenesis and cancer management, whereas HDACs are well-known regulators o

Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis

In the present study, two novel series of compounds incorporating naphthyl and pyridyl linker were synthesized and biological assays revealed 5-((6-(2-(5-(2-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethoxy) naphthalene-2-yl)methylene)thiazolidine-2,4-dione (14b) as the most potent dual inhibitors of vascular endothelial growth factors receptor-2 (VEGFR-2) and histone deacetylase 4 (HDAC4). Compounds 13b, 14b, 17f, and 21f were found to stabilize HDAC4; where, pyridyl linker swords were endowed with higher stabilization effects than naphthyl linker. Also, 13b and 14b showed best inhibitory activity on VEGFR-2 as compared to others. Compound 14b was most potent as evident by in-vitro and in-vivo biological assessments. It displayed anti-angiogenic potential by inhibiting endothelial cell proliferation, migration, tube formation and also suppressed new capillary formation in the growing chick chorioallantoic membranes (CAMs). It showed selectivity and potency towards HDAC4 as compared to other HDAC isoforms. Compound 14b (25 mg/kg, i.p.) also indicated exceptional antitumor efficacy on in-vivo animal xenograft model of human colorectal adenocarcinoma (HT-29). The mechanism of action of 14b was also confirmed by western blot.

Synthesis method of chalcone derivative

The invention provides a synthesis method of a chalcone derivative, which comprises the following steps: adding polyphosphoric acid PPA and a solvent 1, 4-dioxane into a container, sequentially adding98% concentrated sulfuric acid, substituted benzaldehyd

On the development of a nucleophilic methylthiolation methodology

Methylthiolation reactions are usually explored to access organosulfur compounds using methanethiol, an extremely flammable and toxic compound. Herein, methylthiomethyl esters were successfully applied as novel methylthiolation reagents in a low cost, transition-metal-free methodology. These reagents allowed the methylthiolation of a wide scope of chalcones, acyl ester derivatives and Morita-Baylis-Hillman acetates with good group tolerance, affording the methylthiolated products in moderate to excellent yields. The reaction mechanism was investigated through several control experiments, as well as by theoretical calculations employing Density Functional Theory. The results strongly support that a sulfurane and a sulfonium ylide appear as key intermediates and that a Pummerer type rearrangement is also crucial for the formation of this novel reagent. Furthermore, the methylthiolation mechanism is likely to proceed through the nucleophilic attack of the reagent, followed by an entropically favoured step involving the acetate attack to the positively charged species, then releasing the product. This journal is

Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine-2,5-dione Hybrids as Potential Antitumor Agents

In search of novel and effective antitumor agents, pyrazoline-substituted pyrrolidine-2,5-dione hybrids were designed, synthesized and evaluated in silico, in vitro and in vivo for anticancer efficacy. All the compounds exhibited remarkable cytotoxic effects in MCF7 and HT29 cells. The excellent antiproliferative activity toward MCF7 (IC50=0.78±0.01 μM), HT29 (IC50=0.92±0.15 μM) and K562 (IC50=47.25±1.24 μM) cell lines, prompted us to further investigate the antitumor effects of the best compound S2 (1-(2-(3-(4-fluorophenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl)pyrrolidine-2,5-dione). In cell-cycle analysis, S2 was found to disrupt the growth phases with increased cell population in G1/G0 phase and decreased cell population in G2/M phase. The excellent in vitro effects were also supported by inhibition of anti-apoptotic protein Bcl-2. In vivo tumor regression studies of S2 in HT29 xenograft nude mice, exhibited equivalent and promising tumor regression with maximum TGI, 66 % (i. p. route) and 60 % (oral route) at 50 mg kg?1 dose by both the routes, indicating oral bioavailability and antitumor efficacy. These findings advocate that hybridization of pyrazoline and pyrrolidine-2,5-dioes holds promise for the development of more potent and less toxic anticancer agents.

Some thiocarbamoyl based novel anticathepsin agents

Cathepsins have emerged as important targets in various tissues degenerative disorders due to their involvement in degradation of extracellular matrices and endogenous protein turnover. Elevated cathepsins levels vis-à-vis decreased concentration of endogenous inhibitors has been reported at different diseased sites. The design and synthesis of specific potential anti-cathepsin agents is therefore of great significance. Most of potential anti-cathepsin agents developed have peptide based structures with an active warhead. Due to oral instability and immunogenic problems related to peptidyl inhibitors drift the synthesis and evaluation of non-peptide cathepsin inhibitors in last two decades. The present work provides a detailed structure activity relationship for developing potential non-peptide anticathepsin agents based on in-vitro inhibition studies of a library of synthesized thiocarbamoyl- non-peptide inhibitors.